Form D · Pharmaceuticals
Inspyr Therapeutics, Inc.
Westlake Village, CA · CIK 0001421204
Offering snapshot reported Jul 7, 2021 · SEC filing
- Reported sold
- $600K Offering amount: $600K
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 7, 2021 | Initial | $600,000 | No comparison | Not reported | SEC filing |
| Feb 2, 2021 | Initial | $600,000 | No comparison | 3 | SEC filing |
| Feb 2, 2021 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Feb 2, 2021 | Initial | $0 | No comparison | 1 | SEC filing |
| Sep 27, 2017 | Initial | $320,000 | No comparison | 4 | SEC filing |
| Apr 27, 2017 | Amendment | $290,431 | $90,431vs Apr 3, 2017 | 21 | SEC filing |
| Apr 3, 2017 | Initial | $200,000 | No comparison | 16 | SEC filing |
| Dec 19, 2016 | Initial | $1,000,000 | No comparison | 5 | SEC filing |
| Jan 6, 2016 | Initial | $2,492,500 | No comparison | 4 | SEC filing |
| Jul 27, 2015 | Initial | $2,513,894 | No comparison | 5 | SEC filing |
| Dec 9, 2014 | Initial | $280,000 | No comparison | 1 | SEC filing |
| Jun 30, 2014 | Initial | $773,000 | No comparison | 12 | SEC filing |
| Sep 10, 2013 | Amendment | $5,200,032 | $200,000vs Sep 5, 2013 | 75 | SEC filing |
| Sep 10, 2013 | Amendment | $5,000,032 | $0vs Sep 5, 2013 | 73 | SEC filing |
| Sep 5, 2013 | Initial | $5,000,032 | No comparison | 73 | SEC filing |
| Apr 5, 2013 | Amendment | $1,869,000 | $988,000vs Jan 18, 2013 | 29 | SEC filing |
| Jan 18, 2013 | Initial | $881,000 | No comparison | 9 | SEC filing |
| May 24, 2011 | Initial | $2,249,750 | No comparison | 6 | SEC filing |
| Mar 14, 2011 | Amendment | $4,145,578 | $410,738vs Feb 15, 2011 | 27 | SEC filing |
| Mar 4, 2011 | Amendment | $4,034,883 | $300,043vs Feb 15, 2011 | 22 | SEC filing |
| Feb 15, 2011 | Initial | $3,734,840 | No comparison | 16 | SEC filing |
| Jun 21, 2010 | Initial | $2,695,000 | No comparison | 32 | SEC filing |
| Sep 18, 2009 | Initial | $240,000 | No comparison | 5 | SEC filing |
| Aug 3, 2009 | Amendment | $3,038,000 | $906,666vs Jul 8, 2009 | 31 | SEC filing |
| Jul 8, 2009 | Initial | $2,131,334 | No comparison | 17 | SEC filing |
| Jul 8, 2009 | Initial | $750,000 | No comparison | 12 | SEC filing |
| Jul 7, 2009 | Initial | $2,320,000 | No comparison | 42 | SEC filing |
| Dec 12, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-405491
Source: Form D, filed Jul 7, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nancy Jean Barnabei | Executive |
| Richard Buller | Director |
| Michael Cain | Director, Executive |
| Craig Dionne | Director, Executive |
| John Farah | Director |
| Peter Grebow | Director |
| Bo Jesper Hansen | Director |
| Christopher Lowe | Director, Executive |
| John Montgomery | Director |
| Scott Ogilvie | Director |
| Scott Oglive | Director |
| Russell Richerson | Executive |
| Ronald Shazer | Executive |
| Claire Thom | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2629 Townsgate Rd Suite 215
Westlake Village, CA, 91361
Westlake Village, CA, 91361